JP Morgan Chase’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-11
Closed 6281
2018
Q4
$0 Buy
+11
New +$7 ﹤0.01% 6165
2018
Q1
Sell
-100
Closed 5833
2017
Q4
$0 Hold
100
﹤0.01% 5748
2017
Q3
$0 Hold
100
﹤0.01% 5415
2017
Q2
$0 Hold
100
﹤0.01% 5498
2017
Q1
$0 Buy
+100
New +$314 ﹤0.01% 5430
2016
Q2
Sell
-432
Closed -$5K 5154
2016
Q1
$5K Buy
432
+374
+645% +$7.43K ﹤0.01% 4389
2015
Q4
$2K Buy
+58
New +$1.75K ﹤0.01% 4559
2015
Q3
Sell
-2,674
Closed -$158K 4239
2015
Q2
$158K Buy
+2,674
New +$189K ﹤0.01% 3840
2013
Q4
Sell
-1,014
Closed -$28K 4377
2013
Q3
$28K Buy
+1,014
New +$32.6K ﹤0.01% 4298

JP Morgan Chase's PTX Position: Q1 2019 in Review

JP Morgan Chase sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 11 shares.

JP Morgan Chase first reported a position in PTX in Q3 2013 and held it in 9 quarters. The position peaked at $158K in Q2 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.

  • JP Morgan Chase reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
  • JP Morgan Chase sold 11 Pernix Therapeutics Holdings, Inc. shares in Q1 2019.
  • JP Morgan Chase first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2013 and held it in 9 quarters.
  • JP Morgan Chase's Pernix Therapeutics Holdings, Inc. position peaked at $158K in Q2 2015.
  • 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.

Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.